• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NEPH

    Nephros Inc.

    Subscribe to $NEPH
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.

    IPO Year:

    Exchange: NASDAQ

    Website: nephros.com

    Recent Analyst Ratings for Nephros Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Nephros Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Nephros Hires Judy Krandel as Chief Financial Officer

      SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

      11/1/23 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Appoints Joe Harris to Its Board of Directors

      SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

      9/8/22 4:00:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Nephros Appoints Wes Lobo to Chief Commercial Officer

      SOUTH ORANGE, NJ, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(NASDAQ:NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced the appointment of Wes Lobo to the role of Chief Commercial Officer. Mr. Lobo first joined Nephros in February 2021 as Chief Marketing Officer. In the expanded role of Chief Commercial Officer, he will be responsible for all commercial strategy and operations including sales, marketing, business development, product management, and customer service. "As a growth-focused business, Nephros requires a unified commercial organization bui

      9/1/21 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Hires Wes Lobo as Chief Marketing Officer

      SOUTH ORANGE, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Wes Lobo as Chief Marketing Officer, reporting directly to Nephros Chief Executive Officer, Andy Astor. In this role, Wes will be responsible for driving the company’s strategic growth through innovative solutions, go-to-market strategies, and marketing. “Wes brings more than 20 years of expertise in the water business, with broad and deep experience across marketing, strategy, product management, sales, engineering, and leaders

      2/18/21 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC

      SOUTH ORANGE, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City. Robert Banks, CEO and Judy Krandel, CFO of Nephros, Inc. will be hosting one-on-one and group investor meetings. If you would like to schedule a 1x1 investor meeting please make sure you are registered here: The conference offers emerging growth and dynamic publicly traded comp

      12/4/24 9:00:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Launches New HydraGuard 20" UltraFilter

      New Filter Targets Additional Industries and Water Quality Compliance SOUTH ORANGE, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH) Nephros, Inc., a leader in advanced filtration technology, is excited to announce the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader ran

      10/24/24 9:00:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Delivers Critical Disaster Response to Support Hospitals and Care Facilities Impacted by Hurricanes Helene and Milton

      SOUTH ORANGE, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH) Nephros, Inc., a leader in advanced filtration technology, is proud to announce its rapid response to the recent hurricanes which devastated parts of the southeastern United States. Leveraging its significant disaster and emergency response capabilities, Nephros provided crucial water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe supply of water to patients and staff amid recovery efforts. Following natural disasters, access to clean, safe water is paramount for healthcare facilities, where contaminated water may severely compromise patient ca

      10/17/24 9:00:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended June 30, 2024

      Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance

      8/8/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Second Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternativ

      8/1/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results

      Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial HighlightsFourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022Adjusted EBITDA from co

      3/7/24 4:15:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results

      SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor R

      2/29/24 4:30:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Results for Quarter Ended September 30, 2023

      Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities SOUTH ORANGE, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2023. Financial Highlights* Third-quarter net revenue of $3.7 million, an increase of 55%;Third-quarter net loss from continuing operations of $0.2 million, compared to $1.3 million;Third-quarter

      11/8/23 4:15:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. SEC Filings

    See more
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      5/8/25 4:15:47 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Nephros Inc.

      DEFA14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:16:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Nephros Inc.

      DEF 14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:15:38 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Nephros Inc.

      8-K - NEPHROS INC (0001196298) (Filer)

      4/28/25 4:15:15 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NEPHROS INC (0001196298) (Filer)

      3/31/25 9:24:18 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Nephros Inc.

      10-K - NEPHROS INC (0001196298) (Filer)

      3/24/25 11:13:49 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      3/6/25 4:15:34 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Leadership Update

      8-K - NEPHROS INC (0001196298) (Filer)

      3/4/25 4:05:16 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Nephros Inc.

      10-Q - NEPHROS INC (0001196298) (Filer)

      11/14/24 4:03:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      11/13/24 4:15:42 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley FBR initiated coverage on Nephros with a new price target

      B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

      1/26/21 6:12:57 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:15:24 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:13:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:11:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Nephros Inc. (Amendment)

      SC 13G/A - NEPHROS INC (0001196298) (Subject)

      1/6/23 12:04:11 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/28/22 12:05:48 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/10/22 2:19:35 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/10/22 2:19:03 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/10/22 2:18:30 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/10/22 2:18:05 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/10/22 2:17:34 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Krandel Judy

      4 - NEPHROS INC (0001196298) (Issuer)

      3/31/25 4:11:30 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Director Amron Arthur H was granted 22,418 shares, increasing direct ownership by 22% to 125,881 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 6:13:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lask Alisa

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 5:08:03 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Harris Joseph Michael

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 5:07:23 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Director Spandow Oliver J. was granted 33,241 shares, increasing direct ownership by 41% to 114,845 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 5:06:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/30/24 4:35:22 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:49:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Amron Arthur H

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:29:21 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Lask Alisa

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:26:53 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Spandow Oliver J.

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:25:05 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/30/24 4:35:22 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:49:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      3/14/24 4:28:20 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Banks Robert R. Jr. bought $39,647 worth of shares (18,000 units at $2.20), increasing direct ownership by 900% to 20,000 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      12/11/23 4:17:43 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Financials

    Live finance-specific insights

    See more
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended June 30, 2024

      Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance

      8/8/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Second Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternativ

      8/1/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results

      Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial HighlightsFourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022Adjusted EBITDA from co

      3/7/24 4:15:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results

      SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor R

      2/29/24 4:30:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Results for Quarter Ended September 30, 2023

      Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities SOUTH ORANGE, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2023. Financial Highlights* Third-quarter net revenue of $3.7 million, an increase of 55%;Third-quarter net loss from continuing operations of $0.2 million, compared to $1.3 million;Third-quarter

      11/8/23 4:15:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2023 Financial Results Conference Call

      SOUTH ORANGE, NJ, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Wednesday, November 8, 2023 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be added into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

      10/25/23 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Results for Quarter Ended June 30, 2023

      Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022;Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results SOUTH ORANGE, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2023. Financial Highlights* Net revenue from continuing operations of $3.5 million, an increase of 24%Net loss from continuing operations of $0.4 million, compared to $0.7 millionAdjusted EBITDA from continuing operations of ($0.2 million), compared to ($0.4 million) *Stat

      8/9/23 4:15:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Second Quarter 2023 Financial Results Conference Call

      SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its second-quarter financial results on Wednesday, August 9, 2023 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be added into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

      7/26/23 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care